Herpes simplex DNA vaccine - Coridon

Drug Profile

Herpes simplex DNA vaccine - Coridon

Alternative Names: Herpes vaccine - Allied Healthcare Group; HSV-2 vaccine - Admedus; HSV-2 vaccine - Allied Healthcare Group

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator University of Queensland
  • Developer Admedus
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Herpes simplex virus infections

Most Recent Events

  • 19 Oct 2016 Interim efficacy data from a phase IIa trial in Herpes simplex virus infections released by Admedus
  • 04 Mar 2016 Interim efficacy and adverse event data from a phase IIa trial in Herpes simplex virus infections released by Admedus
  • 15 Feb 2016 Admedus completes enrolment in its phase-II trial for Herpes simplex virus infection in Australia (ACTRN12615000094572)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top